Patient Preference for Aesthetic Treatment With AbobotulinumtoxinA or OnabotulinumtoxinA on Facial Sites: A Retrospective Study
Botulinum toxin type A (BoNTA) is used to improve the appearance of facial lines and increase overall attractiveness. Patient satisfaction is an essential measure of treatment success; however, few studies have compared the posttreatment patient approval rates of different BoNTA products. This study analyzed patient satisfaction with abobotulinumtoxinA (ABO [Dysport, Medicis Aesthetics Inc]) treatment results in comparison with prior onabotulinumtoxinA (ONA [Botox Cosmetic, Allergan, Inc]) treatment results. All participants were asked to complete an 11-question survey, which captured information regarding treatment effectiveness, onset, and duration; perceived treatment outcomes using common descriptors; and additional treatment benefits. Surveys were returned anonymously. One hundred ninety-four of 380 surveys (51%) were completed and returned. Many participants underwent BoNTA treatment of crow’s-feet (n=63) or the glabella (n=36); however, relatively few participants reported treatment of the neck (n=9), forehead (n=8), and chin (n=7) areas. Seventy-one participants did not specify a treatment area. For nearly all survey questions, most responses indicated that participants did not perceive a difference between the results of ABO and ONA; those participants who did perceive a difference favored the ABO results. Although most of the surveyed patients could not distinguish between BoNTA products, there was a modest patient preference for ABO.
